effects on RSV and influenza A virus replication.
Influenza virus and respiratory syncytial virus (RSV) are important pathogens involved in respiratory tract infections. Therapy with amantadine, rimantadine, and possibly ribavirin are treatment modalities for influenza A virus infections, and aerosolized ribavirin is used for the treatment of RSV infections. However, (i) the compounds may result in side effects (especially central nervous system toxicity following the use of amantadine) or present difficulties in administration, (ii) neither amantadine nor rimantadine is active against influenza B virus, and (iii) virus mutants that are resistant to amantadine and rimantadine may rapidly arise (1, 2, 4, (5) (6) (7) 12) . Here, we report on a new class of polyanionic compounds, i.e., sulfonic acid polymers, as potent and selective ortho-and paramyxovirus inhibitors that are targeted at virus-cell binding and fusion.
In particular, PAMPS [poly(2-acrylamido-2-methyl-1-propanesulfonic acid)] was found to be active against influenza A virus infection in immunocompetent mice and in SCID (severe combined immunodeficiency) mice.
MATERUILS AND METHODS
Compounds. The chemical structures of sulfonic acid polymers and non-sulfonic acid polymers have been published elsewhere (13, 15) . Poly(4-styrenesulfonic acid) sodium salt (PSS) (molecular weight [MW] = 70,000) was purchased from Aldrich (Milwaukee, Wis.) and poly(anetholesulfonic acid) sodium salt (PAS) (MW = 9,000 to 11,000) was purchased from Sigma Chemical Co. (St. Louis, Mo. measuring antimyxovirus activity have been described previously (8, 10, 14) .
Influence of the incubation time and incubation temperature on antiviral activity. Cells were grown to confluence in 96-well microtiter plates. Then, culture medium was removed and 0.1 ml of maintenance medium (1% fetal calf serum) with or without the test compounds and 0.1 ml of virus suspension containing 50 50% cell culture infective doses (CCID50) were added to each well. After 1 h of incubation at 4 or 35°C, medium containing unadsorbed virus was removed and the cell cultures were gently washed twice with MEM. Then, 0.2 ml of maintenance medium without or with the test compounds was added to the cell cultures. After 5 days of incubation at 35°C, the 50% inhibitory concentrations (IC50s) were determined (8) . Cytotoxicity assay. Cytotoxicity of the compounds was assessed by determining the inhibition of cell growth. Cells were seeded in MEM supplemented with 10% fetal calf serum at 3,000 per well. After cells were allowed to adhere for 24 h, compounds were added in MEM supplemented with 2% MEM. After a 4-day incubation period, the number of cells was determined by means of a Coulter counter and the concentration that inhibits cell proliferation by 50% was calculated.
Protective activity against influenza A virus-induced mortality in mice. The protective activity of the compounds against influenza A virus was assessed by scoring the survival of the mice (9 None of the non-sulfonic acid polymers proved active against RSV or influenza A or B virus. The compounds only inhibited cell growth by 50% at concentrations of :120 ,ug/ml. The antiviral activity of the sulfonic acid polymers (PVS and PSS) against RSV and influenza A virus increased with increasing molecular weight. For example, the PSS IC50s for RSV and influenza A virus replication ranged from 20 to 0.8 ,ug/ml and from 1.6 to 100 ,ug/ml, respectively, for MWs ranging from 1,800 to 70,000 (data not shown).
To understand the mechanism of antimyxovirus activity of these compounds, we next determined the inhibitory effects of PSS, PAMPS, and dextran sulfate on RSV and influenza A virus following incubation of the test compounds with the cells at different times and temperatures. When the compounds were present either during or after the 1-h adsorption period at 4 or 35°C, they proved as effective in inhibiting RSV-induced cytopathicity as when they were present during and after the virus adsorption period ( tion in MDCK cells (Table 3 ). In contrast, the test compounds were ineffective when they were present only during virus adsorption at either 4 or 35°C (except for PSS present for 1 h at 35°C). These data suggest that the sulfonic acid polymers interfere with the virus-cell binding and/or virus-cell fusion process.
In vivo activity of sulfonic acid polymers. Since PAMPS proved to be a potent and highly selective inhibitor of influenza A virus replication in vitro, we further investigated whether topical administration of PAMPS may protect immunocompetent and SCID mice against (mouse-adapted) influenza A virus infection. As shown in Table 4 , when the i.n. infection of immunocompetent mice was carried out in the presence of 10 mg of PAMPS per kg of body weight all animals survived. PAMPS, as a single i.n. dose of 10 mg/kg but not at 1 mg/kg, also completely inhibited the formation of lung lesions and the replication of virus in the lungs (Table 4) . Infected mice developed a wasting syndrome, and as the result of inflammation, the lung weight increased. Therefore, these animals had an increased lung index compared with that for uninfected mice. Infected mice treated with PAMPS (10 mg/kg) had a Table 2 for an explanation of conditions and determination of values.
lung index comparable to that of uninfected animals (Table 4) . Also, when PAMPS was administered i.n. to SCID mice as a single dose of 50 mg/kg at the time of infection, it completely protected the animals against virus-associated mortality (data not shown). A lower dose of PAMPS (5 mg/kg), like dextran sulfate (5 and 50 mg/kg), had no protective effect. However, when PAMPS was administered i.n. at a dose of 10 or 100 mg/kg 1 h before or 1 or 3 h after infection, no significant effects on survival were noted (data not shown).
DISCUSSION
We demonstrated that a new class of sulfonic acid polymers elicits potent and selective inhibitory activity against RSV and influenza A virus in vitro. In particular, PAMPS was found to be 5-to 25-fold more potent than dextran sulfate and ribavirin. We have previously described the potent activity against human immunodeficiency virus type 1 by the sulfonic acid polymers, including PSS, PAS, PVS, and PAMPS, and their mechanism of action, which can be ascribed to inhibition of virus adsorption to the cells (13, 15) . To clarify the mechanism of antimyxovirus activity of the sulfonic acid polymers, we also focused our investigations on the early events in the virus replicative cycle, i.e., the virus-cell binding process (adsorption) and virus-cell fusion process.
Orthomyxovirus (influenza virus) binds to the target cell surface receptor through the viral HAl glycoprotein. Virus entry into the cells occurs via receptor-mediated endocytosis, whereby the viral envelope fuses with the endosomal membrane and the virus genome is released into the cytoplasm. This process is mediated by the HA2 viral glycoprotein. Endocytosis cannot proceed at a low temperature (4°C); it requires a higher temperature (35°C). Thus, a 1-h incubation at 4°C permits adsorption of the virus to the cells but not endocytosis. On the other hand, paramyxovirus (RSV) infection is initiated by adsorption of the virus (via the viral G glycoprotein) to receptors of the target cells. Then, the viral genome is internalized by fusion of the viral envelope with the plasma membrane through mediation of the viral Fl glycoprotein. Interaction of the viral G glycoprotein with the cellular receptor can occur at 4°C, whereas virus-cell fusion requires a higher temperature (i.e., 35°C) (3). The results obtained with PSS and PAMPS but not those obtained with dextran sulfate against RSV (Table 2) suggest that the polysulfonates inhibit both the process of virus adsorption to the cells and the virus-cell fusion process. Moreover, since the compounds still prove effective when added after a 1-h incubation period at 37°C, a point at which fusion is assumed to have at least in part taken place, they probably also act on a yet unidentified postfusion event. In contrast, they do not inhibit the adsorption of influenza A virus (Table 3 ). Our present findings as well as the findings of Luscher-Mattli (11) , who demonstrated that dextran sulfate inhibits fusion of influenza A virus with liposomal membranes, indicate that the inhibitory effect of the sulfonic acid polymers on the replication of influenza A virus is due to a specific inhibition of virus-cell fusion rather than virus-cell binding (adsorption).
We next evaluated whether PAMPS may be active in vivo. When influenza A virus i.n. infection of mice was carried out in the presence of 10 mg of PAMPS per kg of body weight, virus replication in the lungs and lung consolidation were completely inhibited and all mice survived. No such activity was observed with dextran sulfate. Also in immunodeficient (SCID) mice, PAMPS, in contrast to dextran sulfate, efficiently protected the animals against virus-associated mortality. No side effects on the mice, whether immunocompetent or -deficient, were noted 
